# A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas

> **NCT00521560** · PHASE2 · COMPLETED · sponsor: **Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH** · enrollment: 28 (actual)

## Conditions studied

- Primary Non-Hodgkin-Lymphoma
- Refractory Non-Hodgkin-Lymphoma
- CD20+ Aggressive Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Zevalin

## Key facts

- **NCT ID:** NCT00521560
- **Lead sponsor:** Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2009-08
- **Final completion:** 2012-08
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2013-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521560, "A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00521560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*